Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 18/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706140 | 0.93 | TTK (0.69) | TTKADORA3PIK3CBMAPK8PTK2 | |
| SCHEMBL2956334 | 0.92 | TTK (0.77) | TTKADORA3PIK3CBMAPK8PTK2 | |
| SCHEMBL29446172 | 0.91 | TTK (0.77) | TTKADORA3PIK3CBMAPK8PTK2 | |
| SCHEMBL2946927 | 0.91 | TTK (0.77) | TTKADORA3PIK3CBMAPK8PTK2 | |
| SCHEMBL3702624 | 0.91 | TTK (0.66) | TTKADORA3PIK3CBMAPK8PTK2 | |
| SCHEMBL4766744 | 0.90 | TTK (0.65) | TTKADORA3PIK3CBMAPK8PTK2 | |
| SCHEMBL4765064 | 0.89 | TTK (0.79) | TTKADORA3PIK3CBMAPK8PTK2 | |
| SCHEMBL4764772 | 0.89 | TTK (0.63) | TTKADORA3PIK3CBMAPK8PTK2 | |
| SCHEMBL4764770 | 0.88 | TTK (0.63) | TTKADORA3PIK3CBMAPK8PTK2 | |
| SCHEMBL2954789 | 0.88 | TTK (0.63) | TTKADORA3PIK3CBMAPK8PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | TTK 4589/4885ADORA3 1744/4885PIK3CB 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.